Largest Biotech Companies By Total Asset

Total Asset
Total AssetEfficiencyMarket RiskExp Return
1REGN Regeneron Pharmaceuticals
33.08 B
(0.39)
 1.72 
(0.68)
2BNTX BioNTech SE
23.01 B
 0.14 
 3.75 
 0.53 
3IMAB I Mab
2.61 B
(0.01)
 5.22 
(0.06)
4DNA Ginkgo Bioworks Holdings
1.67 B
 0.13 
 5.53 
 0.71 
5ABCL Abcellera Biologics
1.49 B
 0.09 
 3.90 
 0.36 
6MRVI Maravai Lifesciences Holdings
1.49 B
(0.07)
 6.19 
(0.45)
7CPRX Catalyst Pharmaceuticals
470.11 M
 0.10 
 1.90 
 0.19 
8VALN Valneva SE ADR
460.06 M
(0.34)
 2.61 
(0.88)
9APGE Apogee Therapeutics, Common
401.4 M
(0.02)
 3.38 
(0.05)
10CNTA Centessa Pharmaceuticals PLC
360.25 M
 0.13 
 3.88 
 0.52 
11SYRE Spyre Therapeutics
341.86 M
 0.05 
 3.56 
 0.17 
12ABOS Acumen Pharmaceuticals
310.12 M
 0.00 
 4.61 
(0.01)
13INBX Inhibrx
307.89 M
(0.01)
 2.98 
(0.03)
14ARDX Ardelyx
297.58 M
 0.03 
 4.37 
 0.11 
15TCRX Tscan Therapeutics
272.15 M
(0.03)
 3.67 
(0.12)
16TARS Tarsus Pharmaceuticals
265.49 M
 0.33 
 3.45 
 1.15 
17CMRX Chimerix
212.77 M
 0.02 
 3.12 
 0.07 
18SMMT Summit Therapeutics PLC
202.95 M
 0.10 
 9.60 
 0.98 
19MOLN Molecular Partners AG
198.35 M
 0.04 
 7.07 
 0.27 
20GNFT Genfit
173.87 M
 0.03 
 4.37 
 0.14 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value. Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.